Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

18.33
+0.70003.97%
Post-market: 18.930.6021+3.28%19:36 EDT
Volume:1.32M
Turnover:24.06M
Market Cap:1.63B
PE:-4.50
High:18.45
Open:17.29
Low:17.29
Close:17.63
Loading ...

Press Release: Travere Therapeutics to Report First Quarter 2025 Financial Results

Dow Jones
·
Yesterday

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
24 Apr

Travere Therapeutics Price Target Maintained With a $47.00/Share by Guggenheim

Dow Jones
·
14 Apr

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
10 Apr

U.S. RESEARCH ROUNDUP- Carnival, JLL, Microsoft

Reuters
·
10 Apr

Travere Therapeutics Inc : Canaccord Genuity Raises Target Price to $47 From $45

THOMSON REUTERS
·
10 Apr

Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
07 Apr

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

TIPRANKS
·
04 Apr

Travere Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
01 Apr

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Business Wire
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

BUZZ-Travere rises on co's marketing application for kidney disease drug

Reuters
·
17 Mar

Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Reuters
·
17 Mar

Travere Therapeutics Inc: Plans to Submit Amendment to Rems Snda Currently Under Review for Modification of Liver Monitoring

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: Continues to Expect a Rems Modification Pdufa Target Action Date of August 28

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: FDA Notified Company That Rems Monitoring for Embryo-Fetal Toxicity Is No Longer Necessary

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits Snda to FDA for Approval of Filspari® (Sparsentan) for the Treatment of Fsgs

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

GlobeNewswire
·
17 Mar

Travere Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
27 Feb